Cidara gets a nod from Janssen to continue CD388 flu prevention programme

07 Sep 2023
·
Deals
www.pharmaceutical-technology.com
Phase 2VaccineFast TrackClinical ResultPhase 1
Cidara gets a nod from Janssen to continue CD388 flu prevention programme
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Cidara gets a nod from Janssen to continue CD388 flu prevention programme
Preview
Source: Pharmaceutical Technology
Despite retaining ownership of CD388, Janssen is not planning to add the drug to its portfolio, but rather transfer CD388’s rights and obligations to a third party. Image Credit: Prostock-studio / Shutterstock.
Janssen Pharmaceuticals has given Cidara Therapeutics an Election to Proceed Notice for the continued development of CD388 for the prevention of influenza A and B.
The news comes within the required 90-day period that allows Janssen to retain the development and commercialisation rights for CD388. In July, Cidara announced that its partnership with Janssen was still in effect despite the latter’s plans to discontinue the development of JNJ-0953 (CD388).
Recommended Reports
Cidara gets a nod from Janssen to continue CD388 flu prevention programme
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Flu-v in Influenza A Virus, H1N1 Subtype Infections GlobalData
Cidara gets a nod from Janssen to continue CD388 flu prevention programme
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Flu-v in Influenzavirus B Infections GlobalData
View all
CD388 is a drug-Fc conjugate (DFCs) immunotherapy developed using CidaraCidara’s proprietary Cloudbreak platform. Cidara states that CD388 is not a vaccine but acts by inhibiting viral proliferation and allowing for immune-mediated viral clearance, which, as per the company, provides an advantage over current flu vaccines.
The announcement led to an 18% increase in CidaraCidara’s stock price at market open on 6 September, compared to market close on the previous day.
Despite retaining ownership of CD388, Janssen is not planning to add the drug to its portfolio, but rather transfer CD388’s rights and obligations to a third party.
The Election to Proceed also unlocks $7m in milestone payments for CidaraCidara. The US-based company is also in line to receive up to $685m in milestone-based payments and royalties from the CD388 influenza programme.
CD388 received a fast track designation by the US Food and Drug Administration (FDA) in June. It is currently being investigated in two Phase I studies (NCT05285137 and NCT05619536) and one Phase IIa (NCT05523089) trial, with all the trial costs being reimbursed by Janssen.
The interim analysis of the Phase IIa data showed a decrease in influenza virus replication with a single dose of CD388. Additionally, the CD388 treatment group reported lower influenza incidence rates, compared to the placebo arm.
There were no treatment-associated adverse events or trial discontinuations. Cidara expects to deliver complete Phase IIa data to Janssen by the end of 2023.
The development of influenza vaccines has seen an uptick in recent years, with two vaccine candidates currently in Phase II clinical development. Osivax’s OVX836 is currently being evaluated in combination with quadrivalent influenza vaccines (QIVs) in a Phase IIa study (NCT05734040). Imutex’s Flu-v, T-cell vaccine is being evaluated for preventing H1N1, and influenza A and B.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.